GSK Submits NDA For Anti-Malaria Agent In Japan
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline PLC has filed a new drug application for a fixed-dose combination of antiprotozoals atovaquone and proguanil for the prevention and treatment of malaria in Japan.